| Name of the compounds | Main mechanism of action | Application in reprogramming or transdifferentiation | References |
| Signaling pathways | | | | TGF-β signaling pathways | | | | A83-01 | TGF-beta RI (ALK4/5/7) inhibitor | CiNSCs, CiNs, CiBCs, CiPSCs, CiBLPCs, CiCMs, CiEPCs | [16, 27, 28, 30–34, 46, 55–57, 62, 64] | RepSox (E-616452) | TGF-beta RI (ALK5) inhibitor | CiPSCs, CiNs, CiCMs, CiPCs, CiSMCs, CiCCs | [14, 17–19, 21, 22, 40, 41, 45, 52, 61, 69, 71, 79] | SB431542 | Inhibitor of TGF-βRI, ALK4, and ALK7 | CiEPCs, CiNs, CiCMs, CiLCs | [35, 43, 55–57, 59, 75] | IDE 1 | Activator of TGF-β signaling pathway | CiBCs | [64] | DMH1 | Inhibitor of ALK2 | CiNs | [41] | BMP signaling pathways | | | | Dorsomorphin | BMP receptor inhibitor | CiNs | [42] | LDN193189 | BMP type I receptor (ALK2/3) inhibitor | CiNSCs, CiNs | [30, 42, 43] | Wnt signaling pathway | | | | CHIR99021 | GSK3 inhibitor | CiPSCs, EPSs, CiNSCs, CiBLPCs, CiNs, CiCMs, CiPCs, CiSMCs | [15, 17–19, 21, 22, 25–28, 30–34, 39–43, 45, 47, 52, 59, 61, 62, 69, 78, 79] | LiCl | GSK3 inhibitor | CiBCs | [64] | XAV939 | Wnt/beta-catenin inhibitor | EPSs | [26] | IWR1 | Wnt/beta-catenin inhibitor | CiPCs | [52] | CHIR-98014 | GSK3 inhibitor | | | TWS119 | GSK3 inhibitor | | | Tideglusib | GSK3 inhibitor | | | BIO | GSK3 inhibitor | | | AZD2858 | GSK3 inhibitor | | | TDZD-8 | GSK3 inhibitor | | | Indirubin | GSK3 inhibitor | | | PNU-74654 | Wnt/beta-catenin inhibitor | | | IWP-2 | Wnt/beta-catenin inhibitor | | | MAPK/ERK signaling pathway | | | | PD0325901 | Inhibitor of MEK1/2 | CiPSCs, CiCMs, CiNs, EPSs | [22, 26, 42, 61] | SC1 | ERK1 and RasGAP inhibitor | CiCMs | [62] | Rho signaling pathway | | | | Thiazovivin | ROCK inhibitor | CiNs | [43] | Y-27632 | ROCK inhibitor | CiNs, CiBLPCs, CiCMs | [31–33, 40, 42, 46, 47, 58, 62, 78] | Notch signaling pathway | | | | DAPT | Gamma-secretase inhibitor | CiNs, CiBCs | [42, 43, 64] | SHH signaling pathway | | | | Cyclopamine-KAAD | Hedgehog/smoothened inhibitor | CiBCs | [64] | Hh-Ag 1.5 | Smoothened agonist | CiNSCs | [30] | Purmorphamine | Smoothened agonist | CiNs | [42, 43, 46] | Other signaling pathways | | | | A-419259 | An inhibitor of Src family kinases (SFK) | EPS | [26] | dbcAMP | Activates cAMP-dependent protein kinases | | [78] | Forskolin | Adenylyl cyclase activator | CiPSCs, CiNs, CiPCs, CiSMCs, CiLCs | [18, 19, 22, 39–42, 45–47, 52, 59, 61, 69, 75, 78, 79] | Gö6983 | Inhibitor of protein kinase C (PKC) | CiNs | [40] | Indolactam V | Activator of protein kinase C (PKC) | CiBCs | [64] | JNJ10198409 | PDGFR-a and PDGFR-b inhibitor, PDGFR tyrosine kinase inhibitor IV | CiCMs | [62] | SB203580 | P38 MAPK inhibitor | EPSs, CiBCs | [26, 64] | SP600125 | JNK inhibitor | CiNs | [40, 41] | SU16F | PDGFR-b inhibitor | CiCMs | [62] | Celecoxib | COX inhibitor | CiCCs | [71] | Epigenetic modifications | | | | DNA methylation inhibitor | | | | 5-Aza-dC | DNMT inhibitor | CiPSCs | [20] | BrdU (bromodeoxyuridine) | Analog of thymidine | CiPSCs | [19, 22] | DZNep | SAH hydrolase inhibitor | CiPSCs | [18, 21, 22] | RG108 | DNA methyltransferase inhibitor | CiNSCs, CiEPCs, CiNs | [27, 28, 30, 35, 42] | AMI-5 | Protein methyltransferase inhibitor | CiPSCs | [16] | PF-6405761 | BET inhibitor | | | Histone deacetylation inhibitor | | | | NaB | HDAC inhibitor | CiNs, CiCMs | [47, 60] | VPA | HDAC inhibitor | CiPSCs, CiNSCs, CiNs, CiCMs, CiPCs, CiSMCs, CiCCs | [13, 17, 18, 21, 22, 27, 28, 40, 41, 43, 45, 47, 52, 61, 69, 71, 79] | I-BET-762 | BET inhibitor | | | Histone methylation modulator | | | | AS8351 | Inhibitor of histone demethylase | CiCMs | [62] | Bix01294 | Histone methyltransferase inhibitor | CiCMs, CiEPCs, CiNSCs | [27, 28, 35, 62] | BRD 7552 | Increases acetylation of histone H3 and trimethylation of H3K4 and H3K9 | CiBCs | [64] | EPZ5676 | DOT1 inhibitor | CiPSCs | [22] | EPZ004777 | DOT1L inhibitor | CiPSCs | [20, 22] | SGC0946 | DOT1L inhibitor | CiPSCs | [20, 22] | CPI-0610 | BET inhibitor | | | GS-5829 | BET inhibitor | | | Histone acetylation modulator | | | | I-BET151 | Inhibitor of epigenetic reader | CiNs | [39, 45, 78] | INCB057643 | BET inhibitor | | | Metabolic processes | | | | AM580 | RAR agonist | CiPSCs | [20–22] | Bexarotene | RAR agonist | CiAs | [68] | Ch55 | RAR agonist | CiPSCs | [21] | Retinoic acid | RAR ligand | CiNSCs, CiNs | [30, 46] | TTNPB | RAR ligand | CiPSCs, CiNs, CiSMCs, CiCCs | [18, 43, 47, 61, 69, 71] | Bay-K-8644 | Ca2+ channel activator | CiEPCs | [35] | ISX9 | Neurogenesis inducer | CiNs | [39, 42, 78] | LPA | A ligand activator for EDG-2, EDG-4, and EDG-7 | CiBLPCs | [33] | Minocycline hydrochloride | Bind to the bacterial 30S ribosomal subunit and inhibiting protein synthesis | EPSs | [25] | OAC2 | Activator of octamer-binding transcription factor 4 (Oct4) | CiCMs | [62] | Parnate (Tranylcypromine) | Monoamine oxidase inhibitor, LSD1 inhibitor | CiPSCs, CiNSCs, CiCMs, CiSMCs | [15, 17, 18, 21, 30, 59, 61, 69, 79] | P7C3 | Targets NAMPT enzyme | CiNs | [42] | Rolipram | PDE4 inhibitor | | [79] | SMER28 | Autophagy modulator | CiNSCs | [30] | (S)-(+)-Dimethindene maleate | Antagonist of muscarinic M2 and histamine H1 receptors | EPSs | [25] | Vitamin C | A strong antioxidant | CiPSCs, CiNSCs, CiBCs | [22, 27, 28, 64] |
|
|